SLC45A3 and prostate carcinoma: A rare interchromosomal fusion of SLC45A3 with FGFR2 in which the SLC45A3 non-coding exon 1 is fused to the intact coding region of FGFR2 has been found from a brain metastasis of a prostate cancer patient (Wu et al., 2013), indicating that there are also prostate cancer patients that likely benefit from these FGFR inhibitors.